BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 28028005)

  • 1. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
    Singh S; Houng A; Reed GL
    Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha2-antiplasmin plays a significant role in acute pulmonary embolism.
    Matsuno H; Okada K; Ueshima S; Matsuo O; Kozawa O
    J Thromb Haemost; 2003 Aug; 1(8):1734-9. PubMed ID: 12911586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased urokinase and consumption of α
    Longstaff C; Locke M
    J Thromb Haemost; 2019 Jan; 17(1):195-205. PubMed ID: 30451372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
    Bode C; Runge MS; Branscomb EE; Newell JB; Matsueda GR; Haber E
    J Biol Chem; 1989 Jan; 264(2):944-8. PubMed ID: 2492021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.
    Sazonova IY; McNamee RA; Houng AK; King SM; Hedstrom L; Reed GL
    J Thromb Haemost; 2009 Aug; 7(8):1321-8. PubMed ID: 19566545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.
    Urano T; Suzuki Y; Iwaki T; Sano H; Honkura N; Castellino FJ
    Curr Drug Targets; 2019; 20(16):1695-1701. PubMed ID: 31309890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic therapy in the eighties.
    Verstraete M; Collen D
    Blood; 1986 Jun; 67(6):1529-41. PubMed ID: 2423156
    [No Abstract]   [Full Text] [Related]  

  • 10. The fibrinolytic system in man.
    Collen D; Lijnen HR
    Crit Rev Oncol Hematol; 1986; 4(3):249-301. PubMed ID: 2420482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K; Takahashi A; Yoshimoto T
    No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.
    Reilly CF; Fujita T; Hutzelmann JE; Mayer EJ; Shebuski RJ
    Circulation; 1991 Jul; 84(1):287-92. PubMed ID: 1905594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
    Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
    J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological control of tissue plasminogen activator-mediated fibrinolysis.
    Rånby M; Brändström A
    Enzyme; 1988; 40(2-3):130-43. PubMed ID: 3139402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke.
    Papadopoulos SM; Chandler WF; Salamat MS; Topol EJ; Sackellares JC
    J Neurosurg; 1987 Sep; 67(3):394-8. PubMed ID: 3112328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous alpha2-antiplasmin does not enhance glomerular fibrin deposition or injury in glomerulonephritis.
    Kitching AR; Turner AL; O'Sullivan KM; Dewerchin M; Lijnen HR
    J Thromb Haemost; 2003 Sep; 1(9):1992-9. PubMed ID: 12941042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial thrombolysis-related changes after thrombolytic therapy with TPA in patients with acute myocardial infarction.
    Ho CH; Wang SP
    Thromb Res; 1990 May; 58(3):331-41. PubMed ID: 1693793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium.
    Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
    Agents Actions Suppl; 1992; 38 ( Pt 2)():320-9. PubMed ID: 1462839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Termination of bleeding by a specific, anticatalytic antibody against plasmin.
    Zhao T; Houng A; Reed GL
    J Thromb Haemost; 2019 Sep; 17(9):1461-1469. PubMed ID: 31136076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats.
    Witt W; Baldus B; Bringmann P; Cashion L; Donner P; Schleuning WD
    Blood; 1992 Mar; 79(5):1213-7. PubMed ID: 1536947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.